沙利度胺对老年肿瘤化疗患者生活质量影响的临床观察

摘要

Objective To observe the effect of thalidomide on the quality of life of geriatric tumor patients undergoing chemotherapy. Methods Geriatric tumor patients on chemotherapy were divided into two groups, with one receiving thalidomide (n=34)and the other receiving only chemotherapy (n=34).The thalidomide dose was initially 100 mg/day before sleep,which was increased weekly by 50 mg to a final dose of 200 mg/day as long as the patients tolerated the side effects.If not,the original dose was maintained.The two groups were compared in terms of Kamofsky score,QOL score,sleep status,and diet status. Results The Kamofsky and QOL scores improved to a significantly greater extent in the thalidomide group than in the control group (P<0.05).The thalidomide group showed a 58.8% improvement in sleep status and a 55.9% improvement in diet status, both of which were significantly greater than the corresponding improvements in the control group (both 29.4%,P<0.05).Major adverse reactions were similar in both groups (P>0.05) and included marrow depression,nausea and vomiting,and constipation. Conclusion Thalidomide can improve the quality of life in geriatric tumor patients on chemotherapy.%目的：观察沙利度胺（thalidomide，Thd）对老年肿瘤化疗患者生活质量的影响。方法将68例老年肿瘤化疗患者分为Thd组和对照组各34例。Thd组在化疗基础上加服Thd，第1周为100 mg/d，每晚睡前吞服，如患者能耐受不良反应，每周增加50 mg，直至维持目标剂量为200 mg/d，如不能耐受加量者，则维持原剂量。对照组单用化疗。观察两组KPS评分、QOL评分、睡眠和饮食情况等。结果 Thd组患者治疗后KPS评分、QOL评分改善情况较对照组提高，两组比较差异有统计学意义（P<0.05）。Thd组患者睡眠、饮食改善率分别为58.8%、55.9%，对照组二者改善率均为29.4%，两组比较差异有统计学意义（P<0.05）。两组主要毒副反应均为骨髓抑制、恶心呕吐和便秘等，其毒副反应的发生率比较差异无统计学意义（P跃0.05）。结论沙利度胺可以改善老年肿瘤化疗患者的生活质量。